Medtronic is taking another shot at renal denervation to treat drug-resistant hypertension, a year after a pivotal trial for its key product in the space failed to meet its efficacy endpoint.
Verve Medical raises just less than $2 million in an equity offering for its renal denervation device.
Stealthy renal denervation startup Verve Medical raised close to $2 million, according to a regulatory filing, with funding likely slated to help support clinical trials.
Rox Medical's stent-like Coupler implant, designed to treat resistant hypertension, fares well in a pivotal trial as the company gears up for a run at an investigational device exemption from the FDA.
Vascular Dynamics secures a $17 million Series B round to fund clinical trials for its device to treat drug-resistant hypertension.
Vascular Dynamics said it secured $16.85 million in Series B financing to fund clinical trials for its device to treat drug-resistant hypertension.
The FDA grants a humanitarian device exemption for CVRx's Barostim neo legacy device for treating drug-resistant hypertension.
CVRx said yesterday that it won a humanitarian device exemption from the FDA for its Barostim neo legacy device, to treat drug-resistant hypertension.
An analysis of Medtronic's failed Symplicity-3 renal denervation trial highlights several 'confounding' factors that may have contributed to a missed efficacy endpoint, suggesting a way forward for more RDN studies.
Vascular Dynamics reports raising $10 million out of a hoped-for $23 million funding round for its MobiusHD anti-hypertension implant.
Vascular Dynamics said it raised nearly $10 million from a group of unnamed investors for the hypertension implant it's developing.
The Mountain View, Calif.-based startup reported raising $9.7 million in an offering of stock, warrants and other securities as part of a proposed $22.9 million funding round.